Physician profile
Yasser Malik
NPI 1902124811
$8,958.05
in general payments reported to CMS, 2019-2025
34 companies · $1,377 in 2025
The $1,377 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,570 · 2020: $1,673 · 2021: $796 · 2022: $844 · 2023: $567 · 2024: $1,131 · 2025: $1,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,043 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,042.81 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,338.31 | 2021-2025 | |
| Novo Nordisk INC | $1,321.45 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $825.16 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $628.76 | 2019-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $622.31 | 2019-2021 | |
| Pfizer INC. | $601.14 | 2019-2025 | |
| Lilly USA, LLC | $488.79 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Allergan, INC. | $369.45 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $297.69 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $246.24 | 2022-2025 | |
| Amarin Pharma, INC. | $206.23 | 2019-2021 | |
| Corcept Therapeutics | $176.25 | 2019-2020 | |
| Glaxosmithkline, LLC. | $127.81 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Teva Pharmaceuticals USA, INC. | $107.10 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.19 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $64.80 | 2019-2024 | |
| Amgen INC. | $57.02 | 2019-2022 | |
| Corium, LLC | $55.77 | 2023-2025 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.41 | 2019-2021 | |
| Axsome Therapeutics, INC. | $30.14 | 2024-2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $28.56 | 2025 | Voquezna |
| Genentech USA, INC. | $26.73 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.57 | 2019 | |
| Sanofi-Aventis U.S. LLC | $25.24 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.08 | 2025 | Caplyta |
| Lundbeck LLC | $21.10 | 2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $18.33 | 2025 | Rexulti |
| Exact Sciences Corporation | $16.76 | 2023 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $16.02 | 2019 | |
| Abbott Laboratories | $12.23 | 2022 | |
| Ferring Pharmaceuticals INC. | $11.52 | 2019 | |
| Endo Pharmaceuticals INC. | $11.48 | 2020 | |
| Currax Pharmaceuticals LLC | $11.43 | 2020 | |
| Astellas Pharma US INC | $10.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasser Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.